BrianSteingoMD

PubMed

• 16 citations
  Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies.
  Bart Van Wijmeersch, Barry A Singer, Aaron Boster, Simon Broadley, Oscar Fernandez
  Multiple Sclerosis. 2020-11-01
• 26 citations
  Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223
  Brian Steingo, Yaser Al Malik, Ann D Bass, Regina Berkovich, Matthew Carraro
  Journal of Neurology. 2020-06-24
• 37 citations
  Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management.
  Adam Cuker, Ann D Bass, Congor Nadj, Mark A Agius, Brian Steingo
  Multiple Sclerosis. 2020-01-01

Journal Articles

• Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient and physician reported outcomes in relapsing multiple sclerosis: p...  
  Calkwood, J., Cree, B., Crayton, H., Kantor, D., Steingo, B., Barbato,L., Hashmonay, R., Agashivala, N., McCague, K., Tenenbaum, N. and Edwards, K, BMC Neurology, 1/1/2014
• Emerging challenges on the therapeutic landscape of multiple sclerosis: The managed care physician’s perspective and medical director’s perspective  
  Cree, B. A., Steingo, B., Journal of Managed Care Medicine, 1/1/2012

Abstracts/Posters

• Real-world patient retention and satisfaction on fingolimod versus platform injectable disease-modifying therapies in early RRMS: results from PREFERMS
  Heidi Crayton, Brian Steingo, DeRen Huang, Xiangyi Meng, Lesley Schofield, Kristen Johnson, Nadia Tenenbaum on behalf of the PREFERMS investigators, Sunrise Medical Group, Neurology and Neuroscience Associates, Unity Health Network, Novartis Pharmaceuticals Corporation, 68th Congress of the American Academy of Neurology, Multiple locatoins, 1/1/2016
• Patients of African Descent With Active RRMS Demonstrate Clinical and Radiologic Benefits With Alemtuzumab Over 5 Years
  Annette Okai, Keith R Edwards, Brian Steingo, David H Margolin, Sourav Santra, Mitzi Williams, 2016 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC), Multiple locatoins, 1/1/2016
• No Evidence of Disease Activity for 4 Years Following 2 Courses of Alemtuzumab and No Further Treatment: Long-term Responders From CARE-MS II
  Edward J Fox, Hans-Peter Hartung, Eva Havrdova, Brian Steingo, David H Margolin, Karthinathan Thangavelu, Gavin Giovannoni, Central Texas Neurology Consultants, First Medical Faculty, 2016 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC), Multiple locatoins, 1/1/2016
• PREFERMS study: post hoc analyses of treatment satisfaction in patient subgroups, using the Medication Satisfaction Questionnaire
  F.P. Thomas, H. Crayton, B. Steingo, X. Meng, K. Johnson, L. Schofield, N. Tenenbaum, on behalf of the PREFERMS investigators, Sunrise Medical Group, Novartis Pharmaceuticals Corporation, 32st Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Multiple locatoins, 1/1/2016
• Durable Improvement in Clinical Outcomes in Treatment-Naïve Patients with Relapsing-Remitting Multiple Sclerosis Who switched from SC IFNB-1a to Alemtuzumab (CARE-MS I...
  Celia Oreja-Guevara, Raed Alroughani, David Brassat, Alexey N Boyko, Pamela McCombe, Brian Steingo, Bart Van Wijmeersch, David H Margolin, Karthinathan Thangavelu, Cla..., 32st Congress of the European Committee for Treatment and Research in Multiple Sclerosis, London, 1/1/2016
• Join now to see all

Lectures

• Minimizing Risks and Maximizing Efficacy for Management of Multiple Sclerosis 
  CMEducation Resources, LLC, Philadelphia, Pennsylvania - 4/27/2013
• Minimizing Risks and Maximizing Efficacy for Management of Multiple Sclerosis 
  CMEducation Resources, LLC, New Orleans, Louisiana - 3/16/2013
• Minimizing Risks and Maximizing Efficacy for Management of Multiple Sclerosis 
  CMEducation Resources, LLC, Baltimore, Maryland - 3/9/2013
• Minimizing Risks and Maximizing Efficacy for Management of Multiple Sclerosis 
  CMEducation Resources, LLC, Anaheim, California - 3/2/2013
• Minimizing Risks and Maximizing Efficacy for Management of Multiple Sclerosis 
  CMEducation Resources, LLC, Seattle, Washington - 2/23/2013
• Join now to see all